Teva Octreotide Acetate Injection Recall: Sterility Assurance Loss
Teva Pharmaceuticals is recalling Octreotide Acetate Injection 100 mcg/mL (Lot #31327466B, expiring 08/2021) nationwide due to lack of assurance of sterility. The affected product was distributed nationwide, including Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall. Loss of sterility assurance in an injectable drug represents a significant risk of serious health consequences, including infection, sepsis, and other potentially serious complications. Although no illnesses have been reported in the source text, the hazard itself—compromised sterility in an injectable product—creates substantial risk of harm.
Plain-English summary
Teva Pharmaceuticals USA is recalling Octreotide Acetate Injection 100 mcg/mL, 1 mL single-dose vials (NDC 0703-3311-01) because the company cannot assure the sterility of the product. The recall affects Lot #31327466B with an expiration date of 08/2021.
The product was distributed nationwide, including Puerto Rico. A total of 3,067 vials are being recalled. Octreotide Acetate is an injectable prescription medication, and sterility is critical for injectable products to prevent infections and other serious complications.
Patients currently using this medication should consult their healthcare provider immediately about their treatment options and whether they need to switch to an alternative supply. Healthcare providers and pharmacies should stop dispensing this lot and contact patients who may have received vials from this lot.
The recalled product
- Product
- Octreotide Acetate Injection 100 mcg/mL, 1 mL single-dose vial, Rx only, Teva Pharmaceuticals USA. Inc. North Wales, PA 19454, NDC 0703-3311-01
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Injectable Pharmaceutical
- Hazard
- sterility-loss
- injection-safety
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 31327466B
- exp. date 08/2021
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27